NovaBridge Biosciences (NASDAQ: NBP) will hold a webcast on Thursday, August 20, 2026, to discuss its financial results for the first half ended June 30, 2026. The company also plans to provide a corporate update during the session.

The webcast is scheduled for 9:00 am ET (9:00 pm China Standard Time). Investors can access the live broadcast through dedicated links for China and other locations. A replay of the webcast will be archived for at least 30 days after the event and accessible via the Investors page on the NovaBridge Biosciences website.

Corporate Profile

NovaBridge Biosciences is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The company identifies differentiated therapeutic opportunities and generates value-defining clinical evidence. Its strategy involves applying development, financing, and partnering approaches suited to each program.

The portfolio includes programs led by givastomig and VIS-101. The company aims to build a sustainable biotechnology business by repeatedly identifying differentiated innovation and advancing it efficiently.

NovaBridge Biosciences (NASDAQ: NBP) has appointed Srishti Gupta, MD MPP as its new Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. Xi-Yong (Sean) Fu, PhD MBA will step down as Chief Executive Officer to pursue other opportunities and will support the company in an advisory capacity during the transition. Dr. Gupta brings over two decades of transformative leadership experience in biopharmaceuticals, global health, and strategy to the clinical-stage company.

Leadership Transition

The Board of Directors of NovaBridge Biosciences approved the leadership change. Fu Wei, Chairman of the Board, expressed confidence in Dr. Gupta's ability to lead the company forward, citing her global commercial experience and expertise in building strategic partnerships. The Board acknowledged the contributions of Dr. Fu as the outgoing CEO.

Strategic Focus

As CEO, Dr. Gupta will prioritize advancing givastomig toward registration and expanding the ophthalmology franchise under Visara. She aims to establish strategic partnerships to maximize the potential of the company’s medicines for patients and shareholders globally. Her immediate focus is on delivering on the promise of identifying and advancing differentiated assets toward registration and global reach.

Background of Dr. Srishti Gupta

Dr. Gupta most recently served as Chief Executive Officer of Idorsia Ltd, where she executed a full operational and financial turnaround. She spent 18 years at McKinsey & Company, leading the Global Health Practice for over a decade. Dr. Gupta holds a Doctor of Medicine from Harvard Medical School and a Master of Public Policy from Harvard Kennedy School, among other degrees.

About NovaBridge Biosciences

NovaBridge Biosciences is a clinical-stage biopharmaceutical company focused on advancing innovative medicines for areas of significant unmet need. Its pipeline includes givastomig, a potential first-in-class Claudin 18.2-Targeted Immuno Amplifier, and VIS-101, a dual VEGF-A × ANG-2 inhibitor for retinal vascular diseases. The company collaborates with partners like ABL Bio on ragistomig and holds rights to uliledlimab outside of China.